Cipher Pharmaceuticals Inc. (TSE:CPH – Free Report) (NASDAQ:CPHR) – Leede Financial lowered their FY2025 earnings per share estimates for Cipher Pharmaceuticals in a research report issued on Wednesday, March 19th. Leede Financial analyst D. Loe now expects that the company will post earnings per share of $0.87 for the year, down from their prior estimate of $0.93. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals’ FY2026 earnings at $1.00 EPS.
Cipher Pharmaceuticals Price Performance
Shares of CPH opened at C$13.49 on Friday. The stock’s fifty day moving average is C$12.93 and its 200-day moving average is C$14.53. The firm has a market capitalization of C$242.19 million, a price-to-earnings ratio of 14.90 and a beta of 1.20. Cipher Pharmaceuticals has a one year low of C$7.90 and a one year high of C$19.69. The company has a debt-to-equity ratio of 41.22, a quick ratio of 2.67 and a current ratio of 2.00.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.
See Also
- Five stocks we like better than Cipher Pharmaceuticals
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 4 Undervalued Growth Stocks to Buy and Hold for the Long Term
- Investing In Preferred Stock vs. Common Stock
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Health Care Stocks Explained: Why You Might Want to Invest
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
